

Van Naarden Jacob
Form 4
February 15, 2019

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Van Naarden Jacob

2. Issuer Name and Ticker or Trading Symbol
Loxo Oncology, Inc. [LOXO]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___ 10% Owner
 Officer (give title below) ___ Other (specify below)
Chief Operating Officer

(Last) (First) (Middle)
C/O LOXO ONCOLOGY,
INC., ONE LANDMARK SQUARE,
SUITE 1122

3. Date of Earliest Transaction
(Month/Day/Year)
02/15/2019

(Street)
STAMFORD, CT 06901

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(D)	Price \$
Common Stock	02/15/2019		D ⁽¹⁾		19,000	D	235 <u>(1)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Van Naarden Jacob - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Employee Stock Option (Right to Buy)	\$ 3.648	02/15/2019		D ⁽¹⁾		35,026		<u>(2)</u>	06/18/2024	Common Stock	35,026
Employee Stock Option (Right to Buy)	\$ 13.67	02/15/2019		D ⁽¹⁾		78,943		<u>(2)</u>	12/18/2024	Common Stock	78,943
Employee Stock Option (Right to Buy)	\$ 31.69	02/15/2019		D ⁽¹⁾		43,000		<u>(2)</u>	12/15/2025	Common Stock	43,000
Employee Stock Option (Right to Buy)	\$ 26.27	02/15/2019		D ⁽¹⁾		74,000		<u>(2)</u>	12/05/2026	Common Stock	74,000
Employee Stock Option (Right to Buy)	\$ 43.56	02/15/2019		D ⁽¹⁾		35,000		<u>(2)</u>	03/14/2027	Common Stock	35,000
Employee Stock Option (Right to Buy)	\$ 84.88	02/15/2019		D ⁽¹⁾		200,000		<u>(2)</u>	01/03/2028	Common Stock	200,000
Employee Stock Option (Right to Buy)	\$ 139.77	02/15/2019		D ⁽¹⁾		57,000		<u>(2)</u>	01/01/2029	Common Stock	57,000

